Home › Leukemia › Massachusetts › Boston
Pag-aaral pangklinika para sa Leukemia sa Boston, MA
Isang pag-aaral para sa Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Boston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Nagre-recruitPhase 2
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Nagre-recruit
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Nagre-recruitPhase 3
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Nagre-recruitPhase 2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
Nagre-recruitPhase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Nagre-recruitPhase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
Nagre-recruitPhase 2
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Nagre-recruit
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Nagre-recruitPhase 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Nagre-recruitPhase 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Nagre-recruitPhase 1/2
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Nagre-recruitPhase 1
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Nagre-recruitObservasyonal na pag-aaral
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Nagre-recruitPhase 2/3
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Nagre-recruit
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
Nagre-recruitObservasyonal na pag-aaral
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
Nagre-recruitPhase 1
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Nagre-recruitPhase 1/2
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Nagre-recruitPhase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Nagre-recruitPhase 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Nagre-recruit
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Nagre-recruit
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pag-aaral para sa Leukemia sa ibang lungsod
- Houston, TX28 pag-aaral
- New York City, NY19 pag-aaral
- Los Angeles, CA16 pag-aaral
- Chicago, IL16 pag-aaral
- Durham, NC13 pag-aaral
- Baldwin Park, CA12 pag-aaral
- Columbus, OH12 pag-aaral
- Nashville, TN12 pag-aaral
- Philadelphia, PA12 pag-aaral
- Milwaukee, WI11 pag-aaral
- Atlanta, GA11 pag-aaral
- Seattle, WA11 pag-aaral
Iba pang pag-aaral sa Boston
- Kanser sa Suso111 pag-aaral
- Non-Small Cell Lung Cancer90 pag-aaral
- Kanser (lahat ng uri)86 pag-aaral
- Colorectal Cancer63 pag-aaral
- Metastatic Cancer63 pag-aaral
- Kanser sa Baga62 pag-aaral
- Kanser sa Ovary61 pag-aaral
- Kanser sa Prostate59 pag-aaral
- Depression52 pag-aaral
- Kanser ng Endometrium50 pag-aaral
- Pagkabigo ng Puso44 pag-aaral
- Acute Myeloid Leukemia44 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.